The role of serotonin in declarative memory: A systematic review of animal and human research

Coray, Rebecca; Quednow, Boris B.

doi:10.1016/j.neubiorev.2022.104729

Cited by 26 publications

(15 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cognitive profile of MDMA users is characterized by deficits in declarative memory (which includes semantic and episodic memory) (Kalechstein et al, 2007; Montgomery & Roberts, 2022). This is consistent with the idea of 5‐HT being involved in mnemonic processes (Coray & Quednow, 2022; Meneses, 2017). At the molecular level, memory formation is characterized by functional strengthening of existing synapses and de novo synaptogenesis (Radwanska et al, 2011).…”

Section: Introductionsupporting

confidence: 91%

“…Alterations in central 5‐HTergic signaling pathways were demonstrated to alter FC in the dorsal attention network before (Graf et al, 2013; Madsen et al, 2021). Moreover, decreased attentional functions (Coray & Quednow, 2022; Knorr et al, 2019) have been found after acute administration of selective serotonin reuptake inhibitors. Increased FC within networks for domain‐general processes (networks that contribute to a variety of cognitive functions, such as the dorsal attention network) may compensate for the disruption of specialized cognitive functions in case of brain lesion or disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The functional connectome of 3,4‐methyldioxymethamphetamine‐related declarative memory impairments

Coray,

Zimmermann,

Haugg

et al. 2023

Human Brain Mapping

Self Cite

View full text Add to dashboard Cite

The chronic intake of 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) bears a strong risk for sustained declarative memory impairments. Although such memory deficits have been repeatedly reported, their neurofunctional origin remains elusive. Therefore, we here investigate the neuronal basis of altered declarative memory in recurrent MDMA users at the level of brain connectivity. We examined a group of 44 chronic MDMA users and 41 demographically matched controls. Declarative memory performance was assessed by the Rey Auditory Verbal Learning Test and a visual associative learning test. To uncover alterations in the whole brain connectome between groups, we employed a data‐driven multi‐voxel pattern analysis (MVPA) approach on participants' resting‐state functional magnetic resonance imaging data. Recent MDMA use was confirmed by hair analyses. MDMA users showed lower performance in delayed recall across tasks compared to well‐matched controls with moderate‐to‐strong effect sizes. MVPA revealed a large cluster located in the left postcentral gyrus of global connectivity differences between groups. Post hoc seed‐based connectivity analyses with this cluster unraveled hypoconnectivity to temporal areas belonging to the auditory network and hyperconnectivity to dorsal parietal regions belonging to the dorsal attention network in MDMA users. Seed‐based connectivity strength was associated with verbal memory performance in the whole sample as well as with MDMA intake patterns in the user group. Our findings suggest that functional underpinnings of MDMA‐related memory impairments encompass altered patterns of multimodal sensory integration within auditory processing regions to a functional heteromodal connector hub, the left postcentral gyrus. In addition, hyperconnectivity in regions of a cognitive control network might indicate compensation for degraded sensory processing.

show abstract

Section: Introductionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

The functional connectome of 3,4‐methyldioxymethamphetamine‐related declarative memory impairments

Coray,

Zimmermann,

Haugg

et al. 2023

Human Brain Mapping

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, it is unsurprising that serotonin and its receptors play a significant role in learning and memory processes, as well as mood regulation. Interestingly, among serotonin receptors, the 5-HT 1A , 5-HT 6 , and 5-HT 7 subtypes are of particular interest as targets for the treatment of memory deficits (reviewed in [ 58 ] and [ 59 ]) and depressive states [ 60 ]. Our previous studies revealed that JJGW08 was a potent antagonist of 5-HT 1A and D 2 receptors and a weak antagonist of 5-HT 2A and 5-HT 7 receptors [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice

et al. 2023

View full text Add to dashboard Cite

Memory impairments constitute a significant problem worldwide, and the COVID-19 pandemic dramatically increased the prevalence of cognitive deficits. Patients with cognitive deficits, specifically memory disturbances, have underlying comorbid conditions such as schizophrenia, anxiety, or depression. Moreover, the available treatment options have unsatisfactory effectiveness. Therefore, there is a need to search for novel procognitive and anti-amnesic drugs with additional pharmacological activity. One of the important therapeutic targets involved in the modulation of learning and memory processes are serotonin receptors, including 5-HT1A, 5-HT6, and 5-HT7, which also play a role in the pathophysiology of depression. Therefore, this study aimed to assess the anti-amnesic and antidepressant-like potential of JJGW08, a novel arylpiperazine alkyl derivative of salicylamide with strong antagonistic properties at 5-HT1A and D2 receptors and weak at 5-HT2A and 5-HT7 receptors in rodents. First, we investigated the compound’s affinity for 5-HT6 receptors using the radioligand assays. Next, we assessed the influence of the compound on long-term emotional and recognition memory. Further, we evaluated whether the compound could protect against MK-801-induced cognitive impairments. Finally, we determined the potential antidepressant-like activity of the tested compound. We found that JJGW08 possessed no affinity for 5-HT6 receptors. Furthermore, JJGW08 protected mice against MK-801-induced recognition and emotional memory deficits but showed no antidepressant-like effects in rodents. Therefore, our preliminary study may suggest that blocking serotonin receptors, especially 5-HT1A and 5-HT7, might be beneficial in treating cognitive impairments, but it requires further investigation.

show abstract

“…A recent in vitro (postmortem) study using the PET radiotracer [ 18 F]2FNQ1P showed a decrease in 5-HT 6 R density in AD patients in the caudate nucleus, a region normally rich in this receptor [ 10 ]. Furthermore, a systematic analysis of animal and human studies by Corey and Quednow on the role of serotonin in declarative memory showed that there is a marked decrease in serotonin in the brain and that 5-HT 1A R antagonists, 5-HT 4 R agonists and 5-HT 6 R antagonists may be helpful in improving this memory [ 11 ]. Over the past several years, our research group has been involved in the search for new 5-HT 6 R ligands among 1,3,5-triazine derivatives [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

New Triazine Derivatives as Serotonin 5-HT6 Receptor Ligands

et al. 2023

View full text Add to dashboard Cite

Since the number of people with Alzheimer’s disease (AD) continues to rise, new and effective drugs are urgently needed to not only slow down the progression of the disease, but to stop or even prevent its development. Serotonin 5-HT6 receptor (5-HT6R) ligands are still a promising therapeutic target for the treatment of AD. 1,3,5-Triazine derivatives, as novel structures lacking an indole or a sulfone moiety, have proven to be potent ligands for this receptor. In present work, new derivatives of the compound MST4 (4-((2-isopropyl-5-methylphenoxy)methyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine), the potent 5-HT6R antagonist (Ki = 11 nM) with promising ADMET and in vivo properties, were designed. The synthesized compounds were tested for their affinity towards 5-HT6R and other receptor (off)targets (serotonin 5-HT2A, 5-HT7 and dopamine D2). Based on the new results, 4-(2-tert-butylphenoxy)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (3) was selected for extended in vitro studies as a potent and selective 5-HT6R ligand (Ki = 13 nM). Its ability to permeate the blood–brain barrier (BBB) and its hepatotoxicity were evaluated. In addition, X-ray crystallography and solubility studies were also performed. The results obtained confirm that 6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine derivatives, especially compound 3, are promising structures for further pharmacological studies as 5-HT6R ligands.

show abstract

The role of serotonin in declarative memory: A systematic review of animal and human research

Cited by 26 publications

References 227 publications

The functional connectome of 3,4‐methyldioxymethamphetamine‐related declarative memory impairments

The functional connectome of 3,4‐methyldioxymethamphetamine‐related declarative memory impairments

Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice

New Triazine Derivatives as Serotonin 5-HT6 Receptor Ligands

Contact Info

Product

Resources

About